Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01505062 · ClinicalTrials.gov registry record · Phase 1
Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01505062 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 9 participants.
The verdict
NCT01505062, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of ascending doses of subretinal injections of SAR421869 in participants with Usher syndrome type 1B. To evaluate for possible biological activity of SAR421869.
Interventions
- DRUG SAR421869
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-03-26 |
| Est. Completion | 2019-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01505062
The ClinicalTrials.gov registry entry for NCT01505062 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAR421869 is the first listed.
NCT01505062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01505062 about?
NCT01505062 is a clinical study titled "Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B". To evaluate the safety and tolerability of ascending doses of subretinal injections of SAR421869 in participants with Usher syndrome type 1B. To evaluate for possible biological activity of SAR421869.
What is the current status of trial NCT01505062?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-03-26. Estimated completion is 2019-08-16.
What interventions are being tested in trial NCT01505062?
The interventions under investigation include: SAR421869 (DRUG).
Who is sponsoring clinical trial NCT01505062?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.